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OBJECTIVEdTo assess the association between serum 25-hydroxyvitamin D (25-OHD) and
incident type 2 diabetes and to determine whether the association is mediated by subclinical
inflammation.
RESEARCH DESIGN AND METHODSdUsing a case-cohort design, baseline levels of
25-OHD were measured in 416 case subjects with incident type 2 diabetes and 1,267 noncase
subjects selected from a source population of 7,936 middle-aged participants in the population-
based Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA)/Cooperative
Health Research in the Region of Augsburg (KORA) study.
RESULTSdA significant inverse association was observed between serum 25-OHD and in-
cident type 2 diabetes after adjustment for diabetes risk factors and season. The hazard ratio (HR)
and 95% CI comparing tertile extremes was 0.63 (0.44–0.90) (Ptrend = 0.010). Further ad-
justment for C-reactive protein, interleukin-6, soluble intercellular adhesion molecule-1, and
interferon-g–inducible protein-10 attenuated this association by 16% (HR 0.73 [0.50–1.05], P =
0.090).
CONCLUSIONSdVitamin D status is inversely related to type 2 diabetes risk and our data
suggest that this association may be partially mediated by subclinical inflammation.
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P rospective studies demonstrated aninverse relationship between vitaminD status determined bymeasurement
of serum or plasma 25-hydroxyvitamin
D (25-OHD) and incident type 2 diabetes
(1–5). However, results have not always
been consistent, especially regarding asso-
ciations in women (2,6). Several mecha-
nisms may explain the link between
vitamin D and type 2 diabetes. These
include direct and indirect effects of 1,25-
OHD, the active vitamin D metabolite, on
insulin secretion and action (7,8). Immu-
nomodulatory effects of vitamin D (7)
could also mediate the association, as it
is well established that subclinical inflam-
mation is an important risk factor for type
2 diabetes (9,10). To date, no prospective
epidemiological study extensively ad-
dressed the mediating role of subclinical
inflammation. Therefore, we assessed the
association between 25-OHD and incident
type 2 diabetes with and without adjust-
ment formarkers of inflammation. Further-
more, we examined possible interactions of
25-OHD with sex and age.
RESEARCH DESIGN AND
METHODSdResults are based on a
prospective case-cohort study within the
population-based Monitoring of Trends
and Determinants in Cardiovascular Dis-
ease (MONICA)/Cooperative Health Re-
search in the Region of Augsburg (KORA)
cohort (10). The final study sample com-
prised 1,683 participants aged 35–74
years (231 male/185 female case subjects;
657 male/610 female noncase subjects).
The subcohort for the case-cohort study
was selected randomly, stratifying by sex
and survey from a source population of
7,936 subjects without diabetes at base-
line, with available blood samples and a
follow-up time of $1 year, as previously
described (10). All participants provided
written informed consent.
Incident diabetes was assessed using
questionnaires or interviews. Incident cases
were validated by contacting the treating
physician or medical chart review. The
mean duration of follow-up (6SD) was
11.06 4.7 years. Further details regarding
study design and assessment of covariables
have been described previously (10,11).
Serum samples collected at baseline were
used to analyze 25-OHD in 2010 using an
enzyme immunoassay (IDS, Frankfurt,
Germany). The intra- and interassay coef-
ficients of variation were 3.3 and 6.3%, re-
spectively. Thirteen inflammation-related
biomarkers were measured (see Table 1)
(12). Biomarkerswith skeweddistributions
were log transformed. Geometric means of
25-OHD and antilogs of SEs were com-
pared with t tests. Cox proportional hazard
models were used to assess associations be-
tween sex-specific tertiles of 25-OHD and
incident type 2 diabetes. To account for the
case-cohort design, correction of variance
estimation was performed (13). Interac-
tions were examined using likelihood ratio
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tests. P, 0.05 was considered statistically
significant. Evaluations were performed
with the SAS software (version 9.2; SAS
Institute, Cary, NC).
RESULTSdBaseline characteristics for
case and noncase subjects are provided in
Supplementary Table 1. The geometric
mean serum 25-OHD concentration was
37.8 nmol/L in case and 42.0 nmol/L in
noncase subjects. Significant inverse
correlations with r less than 20.10 were
observed between 25-OHD and solu-
ble intercellular adhesion molecule-1,
interleukin-6, interferon-g–inducible
protein-10/CXCL10, and C-reactive pro-
tein (Supplementary Table 2). Therefore,
these four markers of inflammation were
considered potential mediating factors.
After adjustment for age, sex, survey,
and season, high 25-OHD was strongly
associated with a reduced risk for type 2
diabetes with a hazard ratio (HR) (95% CI)
of 0.52 (0.38–0.70) comparing tertile ex-
tremes (Ptrend , 0.001) (Table 1). Further
adjustment for “classic” diabetes risk factors
attenuated the association but it remained
statistically significant (HR 0.63 [0.44–
0.90]; Ptrend = 0.010). Additional adjust-
ment for C-reactive protein, interleukin-6,
soluble intercellular adhesion molecule-1,
and interferon-g–inducible protein-10 fur-
ther attenuated the association by 16%.
To examine the effect of residual confound-
ingbybody fat distribution,where available,
we addedwaist-to-hip ratio to the “classical”
risk factor model. The addition of markers
of inflammation to this model attenuated
the HR for the upper tertile of 25-OHD by
18% (Table 1). Linear regression models
showed similar results, but effects remained
significant for model 3 (Supplementary
Table 3). Interaction and stratified analyses
revealed no statistically significant sex dif-
ferences but stronger associations in youn-
ger (,52 years) than in older ($52 years)
subjects. Since the third-order interaction
term 25-OHD*sex*age-group was statisti-
cally significant (P = 0.010), we performed
additional analyses simultaneously stratify-
ing by age-group and sex (Supplementary
Table 4). In women, the inverse associa-
tion was confined to those aged,52 years
(P for age-group*25-OHD interaction =
0.016), whereas in men, differences be-
tween age-groups were less clear (P for
age-group*25-OHD interaction = 0.046).
CONCLUSIONSdThis study demon-
strated an independent association be-
tween serum 25-OHD and incident type 2
diabetes after adjustment for “classic” di-
abetes risk factors. Further adjustment for
markers of inflammation attenuated the
HRs for the upper tertile of 25-OHD by
16–18%, suggesting that the relationship
between 25-OHD and type 2 diabetes risk
may be partially mediated by subclinical
inflammation. Stratified analyses demon-
strated a significant association between
25-OHD and type 2 diabetes in younger
(presumably mainly premenopausal)
women, but not in older (most likely post-
menopausal) women.
Our results are in line with three other
prospective studies reporting inverse asso-
ciations between 25-OHDand incident type
2 diabetes after adjustment for “classic” di-
abetes risk factors (1,2,4,5). Furthermore,
they support results from the Women’s
Health Initiative where no association be-
tween 25-OHD and type 2 diabetes was
seen in postmenopausal women (6). Our
study is the first prospective study on 25-
OHD and type 2 diabetes risk that included
a large panel of markers of subclinical in-
flammation. Inclusion of these markers in
the regression models indicated that sub-
clinical inflammation could be one mediat-
ing factor linking a low vitamin D status
with the development of type 2 diabetes.
The current studyhas several strengths,
including the population-based prospec-
tive design, the large number of incident
case subjects, the long follow-up, and the
availability of many covariables, including
13 markers of subclinical inflammation.
Major limitations are the self-reported
diagnoses of diabetes, single-time-point
Table 1dHRs for type 2 diabetes risk according to baseline levels of serum 25-OHD
Tertiles of 25-OHD P value
T1 T2 T3 for trend
Men: median [lower–upper] (nmol/L) 27.7 [5.08–36.12] 43.9 [36.13–54.70] 68.0 [54.71–153.92]
Women: median [lower–upper] (nmol/L) 27.0 [9.87–33.13] 39.9 [33.14–48.24] 58.0 [48.25–127.69]
Number case/noncase subjects 175/418 145/428 96/421
HR (95% CI)
Model 1* 1.0 0.77 (0.59–1.01) 0.52 (0.38–0.70) ,0.001
Model 2† 1.0 0.77 (0.56–1.06) 0.63 (0.44–0.90) 0.010
Model 3x 1.0 0.85 (0.61–1.17) 0.73 (0.50–1.05) 0.090
Number case/noncase subjects 99/235 104/268 68/293
HR (95% CI)
Model 1a** 1.0 0.91 (0.64–1.29) 0.55 (0.38–0.80) 0.001
Model 2a‡ 1.0 0.89 (0.58–1.38) 0.61 (0.39–0.96) 0.017
Model 2a + WHR| 1.0 0.92 (0.59–1.43) 0.66 (0.42–1.03) 0.036
Model 3a + WHR# 1.0 1.04 (0.66–1.64) 0.78 (0.48–1.27) 0.224
HRs were estimated by Cox proportional hazard models. Correction for SEs was made using the method by Barlow. Weighing was performed using survey- and sex-
specific sampling weights. Tertiles of the weighted distributions in the subcohort, stratified by sex, were used. Tests for trend were conducted, assigning the median
value within each tertile to the corresponding tertile. WHR, waist-to-hip ratio. *Model 1, adjusted for age, sex, survey, and season. †Model 2, adjusted for factors in
model 1 + BMI, lifestyle factors (i.e., smoking status [never smoker, former smoker, current smoker], alcohol consumption [0, 0.1–39.9,$40 g/day for men; 0, 0.1–
19.9,$20 g/day for women], physical activity [inactive, active]), systolic blood pressure, total cholesterol/HDL cholesterol, and parental history of diabetes (negative,
positive, unknown). xModel 3, adjusted for factors in model 2 + C-reactive protein, interleukin-6, soluble intercellular adhesion molecule-1, and interferon-
g–inducible protein-10/CXCL10 (all coded as tertiles). Markers of inflammation, which were available in addition, include interleukin-18, macrophage-migration
inhibitory factor, monocyte chemoattractant protein-1/CCL2, interleukin-8/CXCL8, adiponectin, leptin, RANTES/CCL5, transforming growth factor-b1, and soluble
E-selectin. **Model 1a, adjusted for factors in model 1, based on data of surveys 2 and 3 only with available WHRmeasurements (n = 1,067). ‡Model 2a, adjusted for
factors in model 2 (n = 1,067). |Model 2a + WHR, adjusted for factors in model 2 + WHR (as polynomial of degree 2) (n = 1,067). #Model 3a + WHR, adjusted for
factors in model 3 + WHR (as polynomial of degree 2) (n = 1,067).
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25-OHDmeasurements, and missing data
on fasting glucose or insulin at baseline.
Also, it is conceivable that prior adjustment
for more sophisticated indicators of obesity
and body fat distribution could have di-
minished the risk reduction caused by the
addition of markers of inflammation.
In conclusion, our results suggest that
the relationship between vitamin D status
and incident type 2 diabetes may be par-
tiallymediatedby subclinical inflammation.
Furthermore, they suggest a modulating
role of age and possibly sex hormones that
needs to be clarified in further studies.
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